• Sensorion named Louis J. Arcudi III chief financial officer effective Oct. 7, 2026, based in the Boston area.
• Arcudi was CFO of Amolyt Pharma, which raised USD 138 million in 2023, then was acquired by AstraZeneca in 2024 for up to USD 1.05 billion.
• Arcudi previously served as CEO of Millendo Therapeutics, following an earlier stint as its CFO from 2018 to 2021.
• Outgoing CFO Laurene Danon will step down to pursue new opportunities, remaining as an adviser during the transition.
• Danon joined as interim CFO in October 2023, became CFO in June 2024, then helped execute financings totaling about EUR 125 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensorion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202610070130BIZWIRE_USPR_____20261006_BW781245) on October 07, 2026, and is solely responsible for the information contained therein.